The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 16, 2011
Filed:
Jan. 16, 2008
John S. Debenham, Scotch Plains, NJ (US);
Jeffrey J. Hale, Westfield, NJ (US);
Pei Huo, Millburn, NJ (US);
Christina B. Madsen-duggan, Scotch Plains, NJ (US);
Thomas F. Walsh, Watchung, NJ (US);
Lin Yan, East Brunswick, NJ (US);
John S. Debenham, Scotch Plains, NJ (US);
Jeffrey J. Hale, Westfield, NJ (US);
Pei Huo, Millburn, NJ (US);
Christina B. Madsen-Duggan, Scotch Plains, NJ (US);
Thomas F. Walsh, Watchung, NJ (US);
Lin Yan, East Brunswick, NJ (US);
Merck Sharp & Dohme Corp., Rahway, NJ (US);
Abstract
Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, Alzheimer's disease, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, Huntington's disease movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, cirrhosis of the liver, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and the promotion of wakefulness.